ArticleFrontiers in immunology2013
Prime-boost strategies in mucosal immunization affect local IgA production and the type of th response.
Article in Frontiers in immunology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
42 citing papers in PubMed.
- Parenteral neonatal priming followed by heterologous mucosal booster favors IgMFrontiers in immunology · 2026Article
- A novel TamA + LtgC bivalent vaccine induces potent immunogenic and bactericidal antibodies against Neisseria gonorrhoeae.Medical microbiology and immunology · 2025Article
- Heterologous sequential immunization using chimeric mRNA and protein vaccines with HA-stem and S-RBD enhanced protective mucosal immunity against influenza and COVID-19.Scientific reports · 2025Article
- A Nasal Vaccine Displaying Anthrax Antigen on the Surface ofJournal of microbiology and biotechnology · 2025Article
- Distinct humoral responses induced by heterologous versus homologous prime-boost immunization strategies in early life.Frontiers in immunology · 2025Article
- Intranasal Multiepitope PD-L1-siRNA-Based Nanovaccine: The Next-Gen COVID-19 Immunotherapy.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024Article
- Induction of Superior Systemic and Mucosal Protective Immunity to SARS-CoV-2 by Nasal Administration of a VSV-ΔG-Spike Vaccine.Vaccines · 2024Article
- Effects of prime-boost strategies on the protective efficacy and immunogenicity of a PLGA (85:15)-encapsulated Chlamydia recombinant MOMP nanovaccine.Pathogens and disease · 2024Article
- SARS-CoV-2 mRNA vaccination induces an intranasal mucosal response characterized by neutralizing antibodies.The journal of allergy and clinical immunology. Global · 2023Article
- Live-attenuated vaccine sCPD9 elicits superior mucosal and systemic immunity to SARS-CoV-2 variants in hamsters.Nature microbiology · 2023Article
- Article
- Unadjuvanted intranasal spike vaccine elicits protective mucosal immunity against sarbecoviruses.Science (New York, N.Y.) · 2022Article
- An intranasal vaccine targeting the receptor binding domain of SARS-CoV-2 elicits a protective immune response.Frontiers in immunology · 2022Article
- Article
- Short or Long Interval between Priming and Boosting: Does It Impact on the Vaccine Immunogenicity?Vaccines · 2021Article
- Article
- Article
- Xyloglucan based mucosal nanovaccine for immunological protection against brucellosis developed by supercritical fluid technology.International journal of pharmaceutics: X · 2020Article
- Immunogenicity and Toxicity of Different Adjuvants Can Be Characterized by Profiling Lung Biomarker Genes After Nasal Immunization.Frontiers in immunology · 2020Article
- Novel mucosal adjuvant, mastoparan-7, improves cocaine vaccine efficacy.NPJ vaccines · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Combinations of different delivery routes for priming and boosting represent vaccination strategies that can modulate magnitude, quality, and localization of the immune response. A murine model was used to study T cell clonal expansion following intranasal (IN) or subcutaneous (SC) priming, and secondary immune responses after boosting by either homologous or heterologous routes. T cell primary activation was studied by using the adoptive transfer model of ovalbumin-specific transgenic CD4(+) T cells. Both IN and SC immunization efficiently elicited, in the respective draining lymph nodes, primary clonal expansion of antigen-specific CD4(+) T cells that disseminated toward distal lymph nodes (mesenteric and iliac) and the spleen. After boosting, a significant serum IgG response was induced in all groups independent of the combination of immunization routes used, while significant levels of local IgA were detected only in mice boosted by the IN route. Mucosal priming drove a stronger Th1 polarization than the systemic route, as shown by serum IgG subclass analysis. IFN-gamma production was observed in splenocytes of all groups, while prime-boost vaccine combinations that included the mucosal route, yielded higher levels of IL-17. Memory lymphocytes were identified in both spleen and draining lymph nodes in all immunized mice, with the highest number of IL-2 producing cells detected in mice primed and boosted by the nasal route. This work shows the critical role of immunization routes in modulating quality and localization of immune responses in prime-boost vaccine strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.